Atmo Biosciences news

Atmo Biosciences CEO Mal Hebblewhite was invited to present at Medical Director’s Healthtech Showcase.

In the video below, Mal gives an overview of Atmo Biosciences then talks to showcase host Dominique Powis about Atmo’s journey so far, and how its ingestible gas-sensing capsule can improve diagnosis and treatment for common gastrointestinal disorders.

A Monash University comparative study has found Atmo Biosciences’ novel ingestible gas-sensing capsule to be similar to a validated wireless motility capsule (WMC) when assessing regional gastrointestinal transit time in healthy adults.

Findings from the study, led by Professor Peter Gibson, are being presented in a poster at Australian Gastroenterology Week (AGW), being held virtually this week.

In the study, 60

Atmo Biosciences exhibited at Australian Gastroenterology Week Conference in Adelaide thanks to the generous support of C.R. Kennedy.

CEO Mal Hebblewhite reported plenty of interest from gastroenterologists regarding the two clinical trials Atmo recently commenced with Professor Peter Gibson at Monash University.

There was also lots of discussion about using the Atmo Gas Capsule as a research tool and potential applications in motility, bacterial overgrowth, IBS, and IBD.